M. Dhodapkar

发表

Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

Ahnalee M. Brincks, J. M. Crawford, Stefani N. Thomas, 2022, Open forum infectious diseases.

Benefits of autologous stem cell transplant for elderly myeloma patients in the last quarter of life.

C. Hofmeister, S. Lonial, J. Kaufman, 2021, Transplantation and cellular therapy.

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)

P. Ascierto, J. Larkin, M. Atkins, 2022, Journal for ImmunoTherapy of Cancer.

Reversible encephalopathy after cryopreserved peripheral blood stem cell infusion

S. Goldberg, A. Tefferi, M. Dhodapkar, 1994, American journal of hematology.

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

C. Hofmeister, S. Lonial, B. Barwick, 2020, Blood Cancer Journal.

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Y. Houvras, S. Jagannath, J. Dey, 2022, Blood.

CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

R. Ahmed, A. Nooka, K. Blum, 2022, Clinical Lymphoma Myeloma and Leukemia.

African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction

C. Hofmeister, S. Lonial, J. Kaufman, 2022, Blood.

A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.

T. Owonikoko, S. Ramalingam, Zhengjia Chen, 2022, Clinical lung cancer.

Hemorrhagic pleural effusion and pleural thickening as a complication of chronic lymphocytic leukemia

S. Yale, M. Dhodapkar, H. C. Hoagland, 1993, American journal of hematology.

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

R. Vij, X. Leleu, R. Ananthakrishnan, 2022, Blood.

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

R. Vij, P. Hari, N. Raje, 2022, Blood.

Downregulation of PA28 alpha induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

C. Hofmeister, S. Lonial, B. Barwick, 2022 .